Related Experiment Video
Updated: Mar 31, 2026

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen
José Vicente Hervás1, Silvia Presas-Rodríguez1, Ane Miren Crespo-Cuevas1
1Department of Neurosciences, Multiple Sclerosis Unit, Germans Trias i Pujol Hospital. C/Canyet s/n 08916, Badalona, Spain.
Abstract:
A risk for developing progressive multifocal leukoencephalopathy is a major barrier to natalizumab use. Extended dosing intervals have been proposed as a way to maintain therapeutic efficacy and reduce progressive multifocal leukoencephalopathy incidence. This is the first reported case of progressive multifocal leukoencephalopathy in a patient using an extended dosing regimen (300 mg/6 weeks). A close clinical and imaging monitoring allowed early detection, which is a major prognostic factor. A favorable outcome was seen with a therapy comprising plasma exchange therapy, mirtazapine, mefloquine and cidofovir. Further studies will be needed to assess the potential role of extended dosing intervals to improve prognosis in patients receiving natalizumab and also to measure its impact clinically and/or radiologically.
More Related Videos
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Antiepileptic Drugs: Glutamate Antagonists
Nephrotic Syndrome III : Nursing Management
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Nephrotic Syndrome II : Assessment and Medical Management

